D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.

Aaron Wexler, PhD, a research fellow in the Department of Pathology, Microbiology and Immunology, has received a Helen Hay Whitney Foundation Fellowship.

An inexpensive generic drug once used to prevent gastrointestinal ulcers in people taking daily NSAIDs protects against C. diff infection in mice.

A link between anti-inflammatory drugs such as ibuprofen and C. diff infection suggests caution against overusing such drugs in patients at high risk for infection.

According to the Centers for Disease Control and Prevention, in 2011 in the United States there were almost half a million Clostridium difficile infections, and one in 11 patients 65 or older with a healthcare-associated C. diff infection died within 30 days of diagnosis.

New research reveals a unique mechanism of C. difficile toxin neutralization by a monoclonal antibody, suggesting new therapeutic approaches.

Children who experience recurrent C. diff infections may have fecal inflammatory markers that could predict risk and improve management of these infections.